| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454453 | Lung Cancer | 2017 | 9 Pages |
Abstract
There was no difference in outcome between the platinum compounds cisplatin and carboplatin in first-line treatment of advanced NSCLC in routine care. This is the first report of longitudinal HRQOL data comparing treatments, showing no difference between carboplatin and cisplatin.
Keywords
CCIeCRFROS1HRQOLEORTCTKIMOSECoGTTDC-ros oncogene 1TLKEGFRPFsALKprogression-free survivaloverall survivalSCLCPatient reported outcomestable diseaseprogressive diseaseCRISPRECISTEuropean Organisation for Research and Treatment of CancerLung cancerNSCLCSmall cell lung cancerNon-small cell lung cancerbody mass indexBMICharlson Comorbidity Indexeastern cooperative oncology groupconfidence intervalElectronic case report formAnaplastic lymphoma kinasePalliative careOutpatient careCohort studiesResponse Evaluation Criteria in Solid TumorsPatient-reported outcomesClinical outcomePROPartial responsecomplete responseHealth-related quality of lifeEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ulla von Verschuer, Roland Schnell, Hans Werner Tessen, Jochen Eggert, Adrian Binninger, Lisa Spring, Martina Jänicke, Norbert Marschner, the TLK-Group (Tumour Registry Lung Cancer) the TLK-Group (Tumour Registry Lung Cancer),